Patents by Inventor Vance Lemmon

Vance Lemmon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11926613
    Abstract: Provided herein are compounds of the general Formula (I) which act as kinase inhibitors, e.g. ROCK, S6K, and/or PKC inhibitors, and are useful in neurite growth and axonal growth.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: March 12, 2024
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Hassan Al-Ali, Vance Lemmon, John Bixby
  • Publication number: 20210163444
    Abstract: Provided herein are compounds of the general Formula (I) which act as kinase inhibitors, e.g. ROCK, S6K, and/or PKC inhibitors, and are useful in neurite growth and axonal growth.
    Type: Application
    Filed: October 31, 2018
    Publication date: June 3, 2021
    Inventors: Hassan Al-Ali, Vance Lemmon, John Bixby
  • Publication number: 20210017162
    Abstract: Provided herein are compounds useful in treating a central nervous system disorder associated with neuronal and/or axonal damage, methods for their preparation, and related pharmaceutical compositions. For example provided herein are compounds of Formula (I): and pharmaceutically acceptable salts and compositions including the same.
    Type: Application
    Filed: March 21, 2019
    Publication date: January 21, 2021
    Inventors: Vance Lemmon, Hassan Al-Ali, John Bixby, Marc Giulianotti
  • Publication number: 20170147743
    Abstract: A computing system automatically analyzes various drug or other compound targets using biologic activity data for cellular proteins, and develops a target/anti-target matrix identifying pharmacologically responsive targets intended for drug engagement, and pharmacologically responsive anti-targets intended for avoidance of drug engagement. The system separates compounds into subsets based on biological threshold data and groups proteins through pharmacological similarity. The system ranks protein groupings in generating the matrix and uses the rankings to recommend compounds and compound groupings for testing to treat a pathology. The system compares new compounds against the matrix to recommend new compounds for testing.
    Type: Application
    Filed: November 23, 2016
    Publication date: May 25, 2017
    Inventors: John Bixby, Vance Lemmon, Hassan Al-Ali
  • Patent number: 5969124
    Abstract: The present invention is directed to the isolation and purification of an L1-like molecule (i.e. L1CAM) from human brain. It has been found that the isolated L1CAM molecule supports neurite growth in vitro. Applicants have also cloned and sequenced the entire coding region of human L1CAM, and found that it shows a very high degree of homology to mouse L1cam with 92% identity at the amino acid level. This similarity suggest that L1CAM is an important molecule in normal human nervous system development and nerve regeneration. Overall, there is substantially less homology to chick Ng-CAM; they are 40% identical at the amino acid level but many regions are highly conserved. Comparison of the sequences from human, mouse, chick and Drosophila, indicates that the L1 immunoglobulin domain 2 and fibronectin type III domain 2 are strongly conserved and thus are likely functionally important.
    Type: Grant
    Filed: April 24, 1995
    Date of Patent: October 19, 1999
    Assignee: Case Western Reserve University
    Inventor: Vance Lemmon
  • Patent number: 5872225
    Abstract: The present invention is directed to the isolation and purification of an L1-like molecule (i.e. L1CAM) from human brain. It has been found that the isolated L1CAM molecule supports neurite growth in vitro. Applicants have also cloned and sequenced the entire coding region of human L1CAM, and found that it shows a very high degree of homology to mouse L1cam with 92% identity at the amino acid level. This similarity suggest that L1CAM is an important molecule in normal human nervous system development and nerve regeneration. Overall, there is substantially less homology to chick Ng-CAM; they are 40% identical at the amino acid level but many regions are highly conserved. Comparison of the sequences from human, mouse, chick and Drosophila, indicates that the L1 immunoglobulin domain 2 and fibronectin type III domain 2 are strongly conserved and thus are likely functionally important.
    Type: Grant
    Filed: November 18, 1994
    Date of Patent: February 16, 1999
    Assignee: Case Western Reserve University
    Inventor: Vance Lemmon